PPH
VanEck Pharmaceutical ETF
PPH
VanEck Pharmaceutical ETF
-
NAV$107.51
as of October 05, 2026 -
YTD RETURNS5.71%
as of October 05, 2026 -
Total Net Assets$1.01B
as of October 05, 2026 -
Total Expense Ratio0.36%
-
Inception Date12/20/2011
Overview
Why PPH
- Highly Liquid CompaniesTracks the largest most liquid pharmaceutical companies
- Industry LeadersFavors established industry leaders with meaningful scale
- Global ScopeProvides exposure to U.S. and international equities for global industry representation
VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Performance
Average Annual Total Returns* (%)
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | -3.28 | 0.50 | 7.51 | 23.60 | 13.35 | 10.67 | 8.69 | 10.00 |
| PPH (Market Price) | -3.19 | 0.67 | 7.58 | 23.72 | 13.37 | 10.65 | 8.70 | 10.09 |
| MVIS US Listed Pharmaceutical 25 Index | -3.26 | 0.55 | 7.32 | 23.42 | 13.00 | 10.31 | 8.44 | 9.81 |
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | -3.28 | 0.50 | 7.51 | 23.60 | 13.35 | 10.67 | 8.69 | 10.00 |
| PPH (Market Price) | -3.19 | 0.67 | 7.58 | 23.72 | 13.37 | 10.65 | 8.70 | 10.09 |
| MVIS US Listed Pharmaceutical 25 Index | -3.26 | 0.55 | 7.32 | 23.42 | 13.00 | 10.31 | 8.44 | 9.81 |
Holdings
Book a 15-minute call to learn more about the holdings.
Daily Holdings (%) as of 10/05/2026
Download XLS|
Ticker
|
Holding Name |
% of Net Assets
|
Market Value (US$)
|
|---|---|---|---|
|
LLY |
Eli Lilly & Co |
20.80 |
208,827,448 |
|
MRK |
Merck & Co Inc |
13.01 |
130,652,697 |
|
NVO |
Novo Nordisk A/S |
5.64 |
56,646,021 |
|
PFE |
Pfizer Inc |
5.05 |
50,659,299 |
|
TEVA |
Teva Pharmaceutical Industries Ltd |
4.84 |
48,622,327 |
|
MCK |
Mckesson Corp |
4.73 |
47,442,281 |
|
BMY |
Bristol-Myers Squibb Co |
4.67 |
46,879,156 |
|
COR |
Cencora Inc |
4.48 |
45,008,851 |
|
GSK |
Gsk Plc |
4.41 |
44,232,508 |
|
ABBV |
Abbvie Inc |
3.75 |
37,631,350 |
|
HLN |
Haleon Plc |
3.68 |
36,946,389 |
|
NVS |
Novartis Ag |
3.63 |
36,420,963 |
|
AZN |
Astrazeneca Plc |
3.53 |
35,436,670 |
|
JNJ |
Johnson & Johnson |
3.35 |
33,646,519 |
|
SNY |
Sanofi Sa/France |
3.26 |
32,759,717 |
|
TAK |
Takeda Pharmaceutical Co Ltd |
2.70 |
27,117,969 |
|
ZTS |
Zoetis Inc |
2.57 |
25,816,215 |
|
VTRS |
Viatris Inc |
1.52 |
15,240,648 |
|
JAZZ |
Jazz Pharmaceuticals Plc |
1.37 |
13,744,845 |
|
CORT |
Corcept Therapeutics Inc |
0.83 |
8,327,083 |
|
AXSM |
Axsome Therapeutics Inc |
0.72 |
7,189,802 |
|
ELAN |
Elanco Animal Health Inc |
0.51 |
5,106,439 |
|
DFTX |
Definium Therapeutics Inc |
0.47 |
4,744,355 |
|
OGN |
Organon & Co |
0.29 |
2,948,432 |
|
PRGO |
Perrigo Co Plc |
0.11 |
1,065,152 |
|
-USD CASH- |
-- |
-0.23 |
-2,356,161 |
|
-- |
Other/Cash |
0.32 |
3,214,723 |
Portfolio
- Market Capitalization (%)
- Currency Exposure (%)
- Sector Weightings (%)
- Country Weightings (%)
Sector Weightings (%) as at 09/30/2026
-
Sector
% of Net Assets -
Health Care
99.62 -
Other/Cash
0.38
Country Weightings (%) as at 09/30/2026
-
Country
% of Net Assets -
United States
67.84 -
United Kingdom
11.75 -
Denmark
5.60 -
Israel
4.75 -
Switzerland
3.61 -
France
3.35 -
Japan
2.71 -
Other/Cash
0.38
Fees
Distributions
as of 10/05/2026
Quarterly
1.89%
1.34%
1.99%
Team
Resources
Regulatory Information
-
Name
Frequency - Annually
- Annually
-
Statement of Additional Information (SAI)
Annually - Annually
- Annually
Fund Documents
-
Name
Frequency -
PPH Fund Profile: A Perfect Prescription for Growth Portfolios
- Daily
-
VanEck Tax Information & Distributions
Annually -
NAV & Premium/Discount History
Daily - Annually
Thought Leadership
-
Name
Frequency